SUBSCRIBE
SUBSCRIBE
News   Drug Development

Wyeth and Zealand Pharma Advance the First Orally Available Gap Junction Modifier into Phase I Clinical Trials

October 10, 2007 | 
1 min read
Zealand Pharma A/S (Zealand) today announced that it received a milestone payment from Wyeth (NYSE: WYE) due to Zealand for the advancement of the first orally available gap junction modifier ZP1609 (GAP-134) into phase I clinical trials in the US.
Clinical research Phase I Europe
MORE ON THIS TOPIC
Creative picture image collage banner of guy worker jump from financial charts determined company success.
Immunology and inflammation
Cogent Jumps on Positive Mid-Stage Mastocytosis Data and NDA Plans
July 7, 2025
 · 
1 min read
 · 
Dan Samorodnitsky
Business vision and target. Businessman holding telescope standing on arrow up go to success in career. Concept business, Achievement, Character, Leader, Vector illustration flat
Drug Development
5 Second-Half Biopharma Milestones To Watch
July 7, 2025
 · 
8 min read
 · 
Tristan Manalac
businessman Climbing mountain. Symbol of success, career, leadership and goal
Immuno-oncology
Four Therapies Hanging On in Troubled TIGIT Space
July 7, 2025
 · 
9 min read
 · 
Tristan Manalac
vector illustration arrows miss the target board, concept of lost in focus, failure, fail, mistake
Immunology and inflammation
Late-Stage Stumble for Cosentyx Sets Novartis Back in Autoimmune Condition
July 3, 2025
 · 
2 min read
 · 
Tristan Manalac